Outcome of 42 thousands cases of SARS-CoV-2 in a municipality: Role of symptoms in outcome.
PDF

Palavras-chave

SARS-CoV-2; anosmia; dysgeusia.

Como Citar

Lima, G. F. C. de, Oliveira, R. G. de, Souto, F. J. D., Fontes, C. J. F., Gajardoni, A. C. R., & Azevedo, F. K. S. F. de. (2023). Outcome of 42 thousands cases of SARS-CoV-2 in a municipality: Role of symptoms in outcome. Brazilian Journal of Implantology and Health Sciences, 5(4), 1857–1871. https://doi.org/10.36557/2674-8169.2023v5n4p1857-1871

Resumo

INTRODUCTION: The coronavirus disease 2019 (COVID-19) pandemic is a major public health problem worldwide with high rates of morbidity and mortality. Elderly patients or patients with comorbidities are more likely to develop more severe conditions and consequently have a high rate of hospital lethality. The presence of some symptoms in SARS-CoV-2 infection can be associated with lower rates of mortality and admission to the ICU in patients. The aim of this study was to determine the associations between the clinical and epidemiological characteristics and clinical outcomes of SARS-CoV-2 infection patients.

METHODS: This was a retrospective cohort study of patients with COVID-19 in 2020–2021 in a municipality in the Midwest region of Brazil. The variables analyzed were age, sex, clinical characteristics, clinical results and presence of comorbidities in patients. Associations between the clinical or epidemiological characteristics were analyzed using appropriate tests for categorical variables and continuous normal or parametric distributions. An alpha value of 5% was used as the maximum error limit allowed to reject the null hypothesis in all analysis.

RESULTS: In total, 42,469 patients were analyzed, with lethality rates of 4.4% and 2.9% in 2020 and 2021, respectively. There was a higher prevalence among women (53.8%) and a higher mortality in men (p = 0.000), the elderly (p = 0.000), patients with dyspnea (p = 0.000), and patients with comorbidities (p = 0.000). The presence of headache, sore throat, anosmia, dysgeusia or diarrhea were related with a lower mortality (p = 0.000).

MAIN CONCLUSIONS: This study demonstrated higher lethality, revealing a higher mortality rate in patients who were male, aged over 65 years, with dyspnea, and with comorbidities. However, headache, sore throat, anosmia, dysgeusia, and diarrhea were associated with an improved prognosis. Further studies to elucidate these findings are warranted.

https://doi.org/10.36557/2674-8169.2023v5n4p1857-1871
PDF

Referências

Liu T, Liang W, Zhong H, He J, Chen Z, He G, et al. Risk factors associated with COVID-19 infection: a retrospective cohort study based on contacts tracing. Emerg Microbes Infect 2020; 9(1):1546-1553.

Xu J, Yang X, Yang L, Zou X, Wang Y, Wu Y, et al. Clinical course and predictors of 60-day mortality in 239 critically ill patients with COVID-19: a multicenter retrospective study from Wuhan, China. Crit Care 2020; 6;24(1):394.

Liu Y, Yan L, Wan L, Xiang T, Le A, Liu J, et al. Viral dynamics in mild and severe cases of COVID-19. Lancet Infect Dis 2020; 20(6):656-657.

Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, et al. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan,China. JAMA Internal Medicina. 2020; 180(7):934-943.

Talavera B, García-Azorín D, Martínez-Pías E, Trigo J, Hernández-Pérez I, Valle-Peñacoba G. Anosmia is associated with lower in-hospital mortality in COVID-19. J Neurol Sci. 2020; 15(419):117163.

Purja S, Shin H, Lee J. Is loss of smell an early predictor of COVID 19 severity: a systematic review and meta analysis. Arch Pharm Res. 2021; 44(7):725–740.

Awwad AA, Elhay OMMA, Rabie MM, Awad EA, Kotb FM, Maghraby HM, et al. Impact of Systemic Diseases on Olfactory Function in COVID-19 Infected Patients. Int J Gen Med. 2022; 15:5681–5691

RECOVERY Collaborative Group. Dexamethasone in Hospitalized Patients with Covid-19. N Engl J Med. 2021; 384(8):693-704.

Salama C, Han J, Yau L, Reiss WG, Kramer B, Neidhart JD, et al. Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia. N Engl J Med. 2021; 384(1):20-30.

IBGE - Instituto Brasileiro de Geografia e Estatística. [updated 2022 May

, cited 2022 May 29]. Available from: https://www.ibge.gov.br/cidades-e-

estados/mt/varzea-grande.html.

Boschiero MN, Palamim CVC, Ortega MM, Mauch RM, Marson FAL. One Year of Coronavirus Disease 2019 (COVID-19) in Brazil: A Political and Social Overview. Ann Glob Health. 2021; 87(1):44.

Van Gerwen M, Alsen M, Little C, Barlow J, Genden E, Naymagon L, et al. Risk factors and outcomes of COVID-19 in New York City; a retrospective cohort study. Journal of medical virology. 2020; 93(2).

Noor FM, Islam MM. Prevalence and Associated Risk Factors of Mortality Among COVID 19 Patients: A Meta Analysis. Journal of Community Health. 2020; 45:1270–1282.

Bienvenu LA, Noonan J, Wang X, Peter K. Higher mortality of COVID-19 in males: sex differences in immune response and cardiovascular comorbidities. Cardiovasc Res. 2020; 116(14):2197-2206.

Meyer NJ, Gattinoni L, Calfee CS. Acute respiratory distress syndrome. Lancet. 2021; 398(10300):622–37.

Caronna E, Ballvé A, Llauradó A, Gallardo VJ, Ariton DM, Lallana S, et al. Headache: A striking prodromal and persistent symptom, predictive of COVID-19 clinical evolution. Cephalalgia. 2020; 40(13):1410–1421.

Trigo J, García-Azorín D, Planchuelo-Gómez A, Martínez-Pías E, Talavera B, Hernández-Pérez I, et al. Factors associated with the presence of headache in hospitalized COVID-19 patients and impact on prognosis: a retrospective cohort study. J Headache Pain. 2020; 21(1):94.

Song W, Hui CKM , Hull JH , Birring SS , McGarvey L, Mazzone SB, et al. Confronting COVID-19-associated cough and the post-COVID syndrome: role of viral neurotropism, neuroinflammation, and neuroimmune responses. Lancet Respir Med. 2021; 9(5):533-544.

Cen Y, Chen X, Shen Y, Zhang XH, Lei Y, Xu C, et al. Risk factors for disease progression in patients with mild to moderate coronavirus disease 2019—a multi-centre observational study. Clin Microbiol Infect. 2020; 26(9):1242–1247.

Zeng KI, Gao F, Wang X, Sun Q, Pan K, Wang T, et al. Letter to the Editor: Obesity as a risk factor for greater severity of COVID-19 in patients with metabolic associated fatty liver disease. Metabolism. 2020; 108:154244.

Creative Commons License
Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.

Copyright (c) 2023 Géssica Fernanda Colnago de Lima, Ruberlei Godinho de Oliveira, Francisco José Dutra Souto, Cor Jesus Fernandes Fontes, Alessandra Carreira Rodrigues Gajardoni, Francisco Kennedy Scofoni Faleiros de Azevedo